To examine the postoperative analgesic efficacy and adverse effects of single doses, injected or oral, of pethidine and ketorolac compared with placebo.
Participants included in the review
Patients aged more than 15 years, with moderate or severe post-operative pain, according to a verbal rating scale or a score of at least 30 mm on a 0-100 mm visual analogue scale (VAS).
Outcomes assessed in the review
Total pain relief (TOTPAR), summed pain intensity difference (SPID) or their visual analogue equivalents (VASTOPAR and VASSPID). Pain had to have been recorded using standard pain scales: four-point pain intensity scale (none, mild, moderate or severe); relief scale (none, slight, moderate, good, complete) or their VAS equivalents.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the reviewers performed the selection. The citations of the studies excluded from the review and reasons for exclusion were available from the authors.
Assessment of study quality
All RCTs were scored for quality using a 1-5 score : two possible points for randomisation (one point if 'randomised at all, two points if method of randomisation described); two possible points for blinding (one point if study described as double-blind, two points if the method by which the double-blinding was achieved was given; and one point if the number and reason for patient withdrawals was listed. Each paper was scored independently for quality by two of the authors who met to agree consensus.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction. The data extracted were: type of surgery; study treatment groups; number of patients treated; study duration; dose of pethidine or ketorolac and route of administration; and mean or derived 4 hour TOTPAR, SPID, VASTOTPAR or VASSPID scores. Where available, information on type incidence and severity of adverse effects, including study withdrawals, was also extracted.
Methods of synthesis
How were the studies combined? Studies were combined using quantitative methods. The proportion of patients in individual studies to achieve at least 50% maximum pain relief over 4-6 hours for pethidine i.m, ketorolac i.m and ketorolac oral were calculated using verified equations(see Other Publications of Related Interest nos.1-3) . These were used to calculate relative benefit and risk estimates with 95% CI using a fixed-effect model. Number Needed to Treat (NNT) and Number Needed to do Harm (NNH) with CI were calculated by the method of Cook and Sackett (see Other Publications of Related Interest no.4). The review emphasised results derived from at least three studies using identical doses and routes of administration.
How were differences between studies investigated?
A formal statistical test of heterogenity was not performed.
Results of the review
Eight placebo-controlled studies of 100 mg i.m pethidine (n=203 pethidine and 161 placebo) and six placebo-controlled studies of i.m ketorolac (n=326 ketorolac and 291 placebo) and eight placebo-controlled studies of oral ketorolac (n=410 ketorolac and 380 placebo) were included in the review.
The relative benefit of pethidine i.m. 100mg compared with placebo was 3.2 (95% CI: 2.3, 4.6) with the NNT to produce at least 50% maximal pain relief of 2.9 (95%CI: 2.3,3.9). The relative benefit of ketorolac 30mg i.m compared with placebo was 2.3 (95% CI: 1.8, 3.1) with an NNT of 3.4 (95% CI: 2.5,4.9). The relative benefit of ketoroloc oral 10mg compared with placebo was 4.3 (95% CI: 3.2, 5.8) with an NNT of 2.6 (95% CI: 2.3, 3.1). The NNH for pethidine 100 mg i.m was 2.6 (95% CI: 2.1, 3.6) compared to 7.3 (95% CI: 4.7, 17) for oral ketorolac. The NNH for i.m. ketorolac versus placebo could not be calculated.
